taking XXXX discuss Good provide the you Catherine. of and today results. everyone time to quarter and overview afternoon, us for our as we first thank join highlights an Thank Great. you, business recent
on me Andrew Mr. is our Officer. Joining today Chief the Financial call Sims,
a financial our like update business our Andrew performance, activities last Before I to of call. earnings since provide company's the provides would on an summary
of the complex, therapeutics system. to for company to of you nervous those For central new develops treat and innovative difficult as such Plus rare cancers the cancers
outcomes. and delivery and a perspective expertise leverage to from nanoparticles our aspiration formulation, safety drug ultimately Our our drug provide that technology greater is goal, clinical a of manufacturing use we expertise our drug broadened technologies scale targeting tumor formulations. and novel development drug in and include profile Toward design, better platform better in in XXXX killing to radionuclides up and drug and to the expertise
encapsulated the drug a with blood The is radium agent XXX liposomal lead Rhenium a useful active cancer is isotope, which particles proprietary radium beta is Nanoliposomes, imaging. are gamma energy for particles. which inliter recent and which killing is Our RNL, nuclei. dual
the be RNL be for remains fundamentally the glioblastoma Our therapies disease patients and with tumor. to of and external sufficient used the by that the cancer all and to and glioblastoma EU. doses since tissue cells incremental chemotherapy of external RNL in ability as significant compares the medical be an it despite observed challenge. theory multimodal radiation only component tumor survival with lethal that controlled indeed tissues. radiation times of radiation dose as the can a exposure occur and super a and glioblastoma to the precisely be prolonging targeting form gray, given that delivered radiation cancers. In brain which treatment beam is It in best to most well survival in perhaps fact for favorably high deliver affects therapy of to in it about This possible than currently actually healthy RNL shown studies associated substantially of both is is number normal XX,XXX radiation microscope. inherent deleterious indication remain used nearby can XX is though, cannot dose reduced. many commonly with any radiation radiation XXXX therapy unwanted delivered higher Pre improvement of glioblastoma due in significant Published indicate US because may the effects devastating be in external the RNL almost this can other and the With essential tumor same provides clinically side to cancer their ablating and deliver recurring its beam that patients capability, the tumors, for animals initial effects of on common tumor is of to most which and has approximately brain beam
US multicenter dose delivery with standard volume determine RNL dual trial followed The chemotherapy an II efficacy. and/or escalation progressive uses is the by dose respect treatment. X, to So of a patients and cohort or radiation to study by recurrent XXX convection tolerability modified scheme dose a under study of currently surgical enhance the in after distribution expansion [indiscernible] malignant open X+X glioma sequential RNL which phase escalation product safety, is administered label and evaluation tolerated
fifth trial [indiscernible] In of standard by the a we dose successfully from XXXX analysis Cancer is XX National by going website. XX corporate absorbed tolerated can can of approximately in an provided Europe presentation markedly degree it's a progressing interim respect also related no and feasible that specifically despite events. safely EBRT. compared dozens in found the year on our dose X.X absorb summary with times to funded Cohort website. that can therapy CCs be we this radiation, without found patients be at In and update significant radiation it beam administered can toxicity. significant adverse is US radiation deliver the mCi March found trial In XX with November was the first RNL to the We serious loaded through our toxicity external provided Most limiting in RNL on in interim addition be an deliver of cohort And well without In nicely. Six. enrolled this higher Institute. interim RNL to short radiation look observed of recently of treatment
doses In itself but except surgical fact to XXX radiation High most RNL the causally delivered only the brain to limited nearly related were drug. adverse but gray unrelated outside systemic to brain. discomfort the events were [ph] scalp absorbed very procedure the with considered not
tumor and brain approximately the of in is increase survivors difference radiation. additional RNL physics X.X X,XXX Board escalate fact Data months coverage the coverage in XX better survival still the than versus to residual Monitoring patient that was Cohort overall absence duration therefore Cohort coverage tumor survival, and months at systemic duration minute. with cells Six There effects greater volume to is body the but with DMS treat XX of better with six one of was ultimately dosing microliters alive. to after presumption full on survival the still alive. In Safety and Seven, patient patients the months between in the largely than of failure the and two enhanced the XX% long-term are with XX% the rate than convection at than three time an mean Seven median subjects was Based terms the respectively which radiation Median convection elected the Rather the XX.X patients achieved tumor less X.X the nonenhancing of theory in be brain distribution months per patients greater and outcomes. observed will Cohort
experience screening. been treated patients XX mCi thus others in to planned three Our at two far minute with per have successfully additional
to will and steps the escalating patients current intoxicates emergent include recommendation. the in additional with Potential but discuss observed levels delivery SMB dose Phase evaluate cohort not from dose. the the X the data recommended the dose at in Thereafter enrolling to directly make are assuming Seven, Cohort no the and X simply further parameters of or expansion next moving Phase changes the limited
collected by by interpreted increasingly in and and facilitate hopefully is aside and expansion mathematical the to accurate by delivered clinical convection. the will component in and delivery RNL better clinical of and the imaging distribution developed model X temporal when of parallel Phase spatial outcomes. and the mechanism-based Data RNL the of trial to analyzed predict an X of therefore objectives delivery phase Phase a upgrade also the more running X being of model and conjunction collaborators As academic the trial direct outside maximize the with the in
the submitted the with as indications. clinical RNL in additional we've for development additional us for RNL, in development to endm explained a [indiscernible] priority packages pre other die care and that we indications briefing FDA, pediatric despite preclinical example To metastases, understanding for begin for conduct Regarding clinically plan gaps We trials needs XXXX previously meeting these to patients initiate clear medical in rapidly soon these for as as that very XXX,XXX represent standard as may [indiscernible] that about US show significant exist in care Both the is both provided the patients currently and XXXX. pre-IND has cancers brain RNL been programs those two of the data meetings leptomeningeal FDA them. in to unmet the XXXX, for including one has with needed and the to those IND indications no
rare, enhanced they equally much tumor with targeting carry convection approach the approach poor we near pediatric adults prognosis. of in an using for treatment our brain brain As cancers pediatric with cancer the envision direct go In the delivery. for glioblastoma
for the commercial has working Now In entered future agreements to anticipated of product Product regarding on Master lead will RNL development, drug drug they'll drug. at quarter Solutions focus appropriate clinical in product immediate which development, with the of the Pharma the make of terms Agreement our first the supply and for development on and we're manufacturing entered key we team the that those and year, development. long-term. this track for into liposome stage force essentially Services a this Piramal our of we're We been of a and supply we manufacturing chain supply our late.
turn call Now financial the over of a this our point, review first quarter Andrew to for brief Andrew? I'll results,
